新股消息 | 劲方医药通过港交所聆讯 报告期内持续亏损

Core Viewpoint - Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. is preparing for its IPO on the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1]. Company Overview - Jinfang Pharmaceutical is a biopharmaceutical company focused on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases [3]. - The company has established a product pipeline with eight candidate drugs, five of which are in clinical development, including core products GFH925 and GFH375 [3]. Product Details - GFH925 (fulzerasib) is a newly discovered drug approved for commercialization in China, targeting advanced non-small cell lung cancer (NSCLC) and is the first selective KRAS G12C inhibitor approved in China and the third globally [3]. - GFH375 is an oral small molecule inhibitor targeting KRAS G12D mutations, currently in Phase I/II clinical trials for advanced solid tumor patients with this mutation [3]. Intellectual Property - The company holds 72 authorized patents and has 117 patent applications, including 8 PCT applications [4]. - It has specific patents related to GFH925 in China, the US, the EU, and other jurisdictions [4]. Financial Performance - Revenue for the fiscal years 2023, 2024, and the four months ending April 30, 2025, is approximately RMB 73.73 million, RMB 105 million, and RMB 82.15 million, respectively [5]. - The company reported losses of approximately RMB 508.32 million, RMB 677.64 million, and RMB 66.62 million for the same periods [5][10]. - Gross profit figures for the same periods are RMB 73.05 million, RMB 84.61 million, and RMB 73.46 million, respectively [9].